

### **HoldiPharma's subsidiaries eye revenues of EGP 21.7 bln in FY 2019/20**

HoldiPharma's subsidiary companies aim to increase revenues to EGP 21.7 billion in FY 2019/20, up from EGP 17 billion in FY 2018/19. The subsidiary drugmakers' net profits are expected to reach EGP 656 million, a 208% year-over-year growth. About 68% of their products are still sold for less than EGP 10. HoldiPharma seeks to increase sales by 22% in FY 2019/20 versus 7% in FY 2018/19. Sales of over-the-counter medications surged 27.3% to EGP 338 million in 2018. Sales of profit-generating drugs jumped 30% to EGP 300 million while sales of loss-making medications dropped 6% to EGP 22 million.